Technical Analysis for AGEN - Agenus Inc.
|Grade||Last Price||% Change||Price Change|
AGEN closed down 1.61 percent on Friday, January 18, 2019, on 1.29 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical AGEN trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||Upper Bollinger Band Walk||Strength||0.00%|
|Jan 18||Wide Bands||Range Expansion||0.00%|
|Jan 18||Overbought Stochastic||Strength||0.00%|
|Jan 18||Upper Bollinger Band Touch||Strength||0.00%|
|Jan 17||New Uptrend||Bullish||-1.61%|
|Jan 17||Expansion Breakout||Bullish Swing Setup||-1.61%|
|Jan 17||Pocket Pivot||Bullish Swing Setup||-1.61%|
|Jan 17||Volume Surge||Other||-1.61%|
|Jan 17||Wide Range Bar||Range Expansion||-1.61%|
|Jan 17||Parabolic Rise||Strength||-1.61%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer's disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company's products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more AGEN news...
|52 Week High||6.19|
|52 Week Low||1.54|
|200-Day Moving Average||2.5393|
|50-Day Moving Average||2.5128|
|20-Day Moving Average||2.9115|
|10-Day Moving Average||3.333|
|Average True Range||0.2716|
|Chandelier Exit (Long, 3 ATRs )||3.0652|
|Chandelier Exit (Short, 3 ATRs )||2.7648|
|Upper Bollinger Band||3.851|
|Lower Bollinger Band||1.972|
|Percent B (%b)||0.9|
|MACD Signal Line||0.2494|
|Market Cap||365.94 Million|
|Num Shares||99.7 Million|
|Price-to-Earnings (P/E) Ratio||-2.91|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||4.09|
|Resistance 3 (R3)||4.11||4.00||4.02|
|Resistance 2 (R2)||4.00||3.89||3.99||4.00|
|Resistance 1 (R1)||3.83||3.82||3.78||3.81||3.97|
|Support 1 (S1)||3.55||3.61||3.50||3.53||3.37|
|Support 2 (S2)||3.44||3.54||3.43||3.34|
|Support 3 (S3)||3.27||3.44||3.32|
|Support 4 (S4)||3.25|